ORI, established in 2015 with two funds that primarily invest in global biotech start-ups, is in the process of raising capital for a third fund, which will “invest heavily” in China ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...

Pop Mart’s revenue outside China skyrocketed 375.2% to 5.07 billion yuan ($703 million) in 2024, and Citigroup research estimated Pop Mart’s revenue in America grew between 895% to 900% last year.

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed ...

China's central bank has lowered key interest rates to record lows, aiming to stimulate an economy challenged by weak consumer demand and a property crisis. The cuts follow a temporary easing of ...

The US is dangerously close to falling behind China in biotech, and the government should spend a minimum of $15 billion over the next five years to "unleash" private capital for the sector.

This expansion aligns with China's broader Belt and Road Initiative (BRI), which aims to increase China's economic and cultural influence globally. Experts suggest this move is a calculated step ...

Parliament will meet from Tuesday (20) to Friday (23), according to Secretary General Kushani Rohanadeera.The decision was made at the Committee on Parliamentary Business meeting held last Friday ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...